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specialized diagnostic arrays significantly improves the accuracy
of diagnosis of suspect masses in the pancreas. We have con-
structed diagnostic arrays to only contain genes with diagnostic
and/or prognostic potential for the classification of pancreatic
tissues, augmented with control features. Our results demon-
strate that this setup is suitable to produce reliable, reproducible
and informative expression profiles of pancreatic tissues and
biopsy samples. Expression profiling analysis using the special-
ized diagnostic array in conjunction with conventional cytology
allows the distinction between pancreatic ductal adenocarci-
noma (PDAC) and non-malignant diseases of the pancreas with
almost 100% diagnostic accuracy. We are currently in the process
of analyzing additional tumor entities, such as acinar and neu-
roendocrine tumors, using both the diagnostic array as well as
large scale arrays, in order to develop a multiclass classification
system for the comprehensive diagnosis of different malignan-
cies in the pancreas. In addition, we expect further development
of the array in combination with careful analysis of clinical
patient data to result in the recognition of distinct prognostic
gene expression signatures predicting important clinical param-
eters such as stage of disease, response to therapy, or prognosis.
Specialized DNA arrays thus represent valuable new diagnostic
tools which can significantly expand the range of information
gained in routine diagnostic procedures, thus providing a better
basis for decisions on treatment options and setting the stage
for therapeutic regimens custom tailored to the individual
patient.
doi:10.1016/j.ejcsup.2006.04.016
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Trained neural networks can be used to construct scoring mod-
els for molecular staging in cancer. They offer considerable flex-
ibility for representing nonlinear interactions, but because of
their flexibility they also tend to require substantial ‘‘training’’
data. It often happens that clinical factors are available in a
large collective, but molecular data is available only for a smaller
subset. A hierarchical neural net training architecture is pre-
sented here. Hierarchical nets are trained in levels, the first level
on a large cohort with limited (usually clinical) factors, the sec-
ond and possibly higher levels on cohort subsets with more
(usually molecular) factors, and so on. The scores produced at
the first level are treated as ‘‘factors’’ for the second level, and
so on. In diseases with distinctly classifiable modes or sites of
recurrence (e.g., bone vs. soft tissue in breast cancer), the ‘‘com-
peting’’ risks can be modelled within the neural network archi-
tecture. To test the hypothesis that a molecular staging factor
might signal the particular relapse mode, one can study signifi-
cant correlations between factors and ‘‘hidden’’ nodes of a
trained neural network. A method is also described for using
trained neural nets to generate hypotheses about potential sub-
groups for molecular staging targets. Applications to breast,
colon, and gastric cancer are reviewed.
doi:10.1016/j.ejcsup.2006.04.017
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In the Division of Functional Genome Analysis at DKFZ, we are devel-
oping technologies for the identification, description and evalua-
tion of cellular functions and their regulation by producing and
processing biological information on a genomic scale. Many
chemical and biophysical issues are being addressed in an
attempt to understand the underlying procedural aspects,
thereby establishing superior analysis processes.
Concerning human material, systems are being developed
toward early diagnosis, prognosis and evaluation of the success
of disease treatment with an accentuation on cancer. To this
end, comparative studies on epigenetic and splice variations,
transcription factor binding, transcriptional activity and actual
protein expression are under way. Early diagnosis from body flu-
ids is being worked at that is based on the binding of their com-
ponents to peptide and antibody microarrays.
Combining this data with clinical information permits the
definition of patient sub-groups and may provide a robust
means for diagnosis and prognosis and lead to the identification
of relevant molecular activities. We have established processes –
both experimentally and in the area of bioinformatics – to deal
with this challenge. The combination will not only occur in sil-
ico, since the various molecular levels affect each other exten-
sively. Soon, current in silico systems biology will translate
into ever more complex experimental set-ups that permit an
evaluation of a biological issue in a systemic experimentation.
Similar to research in physics, an iterative interaction of theoret-
ical and experimental systems biology will yield important
insights into function, providing the archetypal platform for an
eventual model of a cell.
doi:10.1016/j.ejcsup.2006.04.018
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Rainer Spang. Max Planck Institute for Molecular Genetics, Berlin,
Germany.
A plethora of computational methods for the diagnosis of can-
cer using gene expression profiling has been suggested. This
might come as a surprise, since diagnosis appears to be a
straightforward classification problem. What can be done with
methods from standard statistics textbooks? Clearly, the prob-
lem is the large number of genes on the arrays. Including them
all in a classification model leads to saturation of the model.
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The consequence is poor performance in practice. However, one
does not need all genes on the array. One can proceed in two
steps, first reducing the number of genes to only a couple of
signature genes using conventional test statistics, and then
solving a low dimensional classification problem using standard
linear discriminant analysis. While this strategy works, the
resulting models have different properties on large-scale data,
than they would have in a low dimensional setting. The
large-scale setting imperatively requires a different kind of sta-
tistical thinking.
In this talk, I will point out the power and the limitations of
conventional statistical methodology in large scale profiling. I will
start with pointing out the specific statistical characteristics of
microarray-based diagnosis. To this end, I will discuss, how to
design a diagnostic microarray study, how to select marker genes,
how to determine an appropriate number of marker genes, how
to combine the expression levels of these genes to a diagnostic
signature, how to evaluate the performance of a signature, and
finally how to document a diagnostic signature for publication.
In all steps I will choose statistical concepts, which are as conven-
tional as possible for these tasks.
doi:10.1016/j.ejcsup.2006.04.019
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Conventional magnetic resonance imaging (MRI) in glioblastoma
models concentrates on high resolution imaging, the description
of pathophysiological changes by perfusion or diffusion weighted
imaging and the characterization of metabolites with magnetic
resonance spectroscopy.
With the advances in molecular biology and MRI there is rap-
idly growing interest in making radiological imaging techniques
more sensitive and specific for monitoring, diagnosing, and dif-
ferentiating biological processes.
The combination of information generated from molecular
genetics, the large number of animal models of human diseases
and new imaging techniques and contrast agents is the driving
force of developments in molecular imaging. Major goals of
molecular imaging by MRI are to image the presence of specific
molecules with targeted contrast agents to track cell migration,
follow changes in gene expression, and to develop strategies
enabling MRI to monitor other specific biological processes.
Encouraging results exist especially in the field of cell tracking
and monitoring gene expression using the signal reduction
caused by iron.
Problems encountered in the molecular imaging of glioblasto-
mas include the creation of a highly specific imaging agent,
access of the specific imaging agent to the molecular target (pas-
sage of the blood–brain barrier (BBB)) and an adequate imaging
quality with strong specific signal. Translation of in vitro concepts
to the in vivo application is often problematic. One major issue is
the size of the specific compound hindering the imaging agent to
pass the BBB or to pass even further to enter the cytoplasm. With
this problem being unsolved further progress needs to be done
before molecular imaging turns into a general imaging tool in ani-
mal models of glioblastoma.
doi:10.1016/j.ejcsup.2006.04.020
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Assessment of gene function following the completion of human
genome sequencing may be done using radionuclide imaging pro-
cedures. These procedures are needed for the evaluation of genet-
ically manipulated animals or new designed biomolecules which
requires a thorough understanding of physiology, biochemistry
and pharmacology. The experimental approaches will involve
many new technologies including in vivo imaging with SPECT
and PET. Nuclear medicine procedures may be applied for the
determination of gene function and regulation using established
and new tracers or using in vivo reporter genes such as genes
encoding enzymes, receptors, antigens or transporters. Visualiza-
tion of in vivo reporter gene expression can be done using radio-
labeled substrates, antibodies or ligands. Combinations of specific
promoters and in vivo reporter genes may deliver information
about the regulation of the corresponding genes. Furthermore,
protein–protein interactions and activation of signal transduction
pathways may be visualized non-invasively. The role of radiola-
beled antisense molecules for the analysis of mRNA content
has to be investigated. However, possible applications are thera-
peutic intervention using triplex oligonucleotides with therapeu-
tic isotopes which can be brought near to specific DNA sequences
to induce DNA strand breaks at selected loci. Imaging of labeled
siRNA’s makes sense if these are used for therapeutic purposes
in order to assess the delivery of these new drugs to their target
tissue.
In gene therapy based on the transfer and expression of sui-
cide genes usually genes coding for the non-mammalian
enzymes, the Herpes simplex virus thymidine kinase (HSVtk)
or the yeast and bacterial cytosine deaminase (CD), have been
used. After infection of the tumor with the recombinant virus,
a non-toxic prodrug is applied systemically, which is subse-
quently converted to a toxic metabolite by the recombinant gene
product. Employing a radiolabeled prodrug and scintigraphic
procedures it is possible to determine the functional activity of
the recombinant enzyme in vivo. This information can be used
to establish a therapeutic window of maximal gene expression
and consecutive drug administration. If the gene therapy
approach is based on the transduction of receptor genes, the
recombinant gene expression in tumor cells is monitored using
radiolabeled ligands. Transfer of transporter genes such as the
sodium iodide transporter may also permit the visualization of
transduction via accumulation of iodide or pertechnetate in
the targeted tissue.
Pharmacogenomics will identify new surrogate markers for
therapy monitoring which may represent potential new tracers
for imaging. Also drug distribution studies for new therapeutic
biomolecules are needed at least during preclinical stages of drug
development. New treatment modalities such as gene therapy
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